Status:
UNKNOWN
Inhaled Budesonide in Transient Tachypnea of the Newborn
Lead Sponsor:
Makassed General Hospital
Conditions:
Respiratory Distress
Eligibility:
All Genders
34+ years
Phase:
NA
Brief Summary
Background: Transient tachypnea of the newborn (TTN) caused by lung edema resulting from delayed absorption of fetal alveolar lung fluid and is a common cause of admission of late preterm and full-ter...
Eligibility Criteria
Inclusion
- Late preterm and term infants (post-menstrual age ≥ 34 weeks) delivered by Cesarean section or vaginal delivery
- Diagnosis of transient tachypnea of the newborn
- The need for Continuous positive airway pressure (CPAP) \>6 hours to obtain the oxygen saturation \>92%
Exclusion
- Meconium aspiration syndrome;
- Respiratory distress syndrome
- Congenital heart Disease
- Non respiratory disorders causing tachypnea (polycythemia or hypoglycemia) resolving with treatment of the disorder
- Pneumonia by chest x-ray
- Suspected sepsis/bacteremia
- Prenatal steroids
Key Trial Info
Start Date :
February 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2021
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04758078
Start Date
February 15 2021
End Date
August 1 2021
Last Update
March 3 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Makassed General Hospital
Beirut, Lebanon, +961